EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses

Kyle T Reid, Sarah J Colpitts, Jessica A Mathews, Abel Santos Carreira, Julia M Murphy, Dorota T Borovsky, Sinthuja Jegatheeswaran, Wenhui Cui, Tommy Alfaro Moya, Nadia Sachewsky, James An, Yubing Xia und 6 weitere

Cell Reports · 2025

DOI: 10.1016/j.celrep.2024.115102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Kyle T Reid und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Toronto General Hospital Research Institut…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Interleukin-10, Lymphocytes, T-Lymphocytes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Toronto General and Western Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-10 (IL-10)-producing group 2 innate lymphoid cells (ILC210) regulate inflammatory immune responses, yet their therapeutic potential remains largely unexplored. Here, we demonstrate that cell therapy with human ILC210 inhibits pathogenic T cell responses in humanized mouse models of graft-versus-host disease (GVHD), resulting in reduced GVHD severity and improved overall survival without limiting the graft-versus-leukemia effect. ILC210 conferred superior protection from GVHD than IL-10-/low ILC2s, and blocking IL-10 and IL-4 abrogated ILC210 protective effects, indicating that these cytokines are important for the protective effects of ILC210. Notably, ILC210 provided comparable protection from GVHD to regulatory T cells without impairing T cell engraftment, instead decreasing intestinal T cell infiltration and suppressing CD4+ Th1 and CD8+ Tc1 cells. CITE-seq of expanded ILC2s revealed CD49d and CD86 are markers that allow for enrichment of ILC210 from conventional ILC2s and tracking of ILC210 in patient studies. Altogether, these findings demonstrate the potential of ILC210 in cell therapies for GVHD and other immune-mediated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseInterleukin-10LymphocytesT-LymphocytesAnimalsHumansMiceImmunity, InnateDisease Models, Animal

Stichwörter der Autor:innen

CP: ImmunologyIL-10ILC2sTregscell therapygraft-versus-host diseasegraft-versus-leukemic effecthematopoietic stem cell transplantimmune toleranceinnate lymphoid cellstransplantation

Substanzen

Interleukin-10

Autor:innen und Institutionen

  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON M5…
  • Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; Postgraduate Medical Education Program, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.

Förderung

  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada
  • Toronto General and Western Hospital Foundation
  • Canada Excellence Research Chairs
  • Canadian Blood Services
  • Canada First Research Excellence Fund
  • Canada Foundation for Innovation

Zitieren

APA

Reid, K. T., Colpitts, S. J., Mathews, J. A., Santos Carreira, A., Murphy, J. M., Borovsky, D. T., Jegatheeswaran, S., Cui, W., Alfaro Moya, T., Sachewsky, N., An, J., Xia, Y., Mortha, A., Lee, J. B., Zhang, L., Novitzky-Basso, I., Mattsson, J., & Crome, S. Q. (2025). Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell Reports. https://doi.org/10.1016/j.celrep.2024.115102

Vancouver

Reid KT, Colpitts SJ, Mathews JA, Santos Carreira A, Murphy JM, Borovsky DT, et al. Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell Reports. 2025. doi:10.1016/j.celrep.2024.115102

BibTeX
@article{Reid2025,
  author = {Reid, Kyle T and Colpitts, Sarah J and Mathews, Jessica A and Santos Carreira, Abel and Murphy, Julia M and Borovsky, Dorota T and Jegatheeswaran, Sinthuja and Cui, Wenhui and Alfaro Moya, Tommy and Sachewsky, Nadia and An, James and Xia, Yubing and Mortha, Arthur and Lee, Jong Bok and Zhang, Li and Novitzky-Basso, Igor and Mattsson, Jonas and Crome, Sarah Q},
  title = {Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2024.115102}
}
Kostenlos starten →